Citius pharmaceuticals, inc. reports fiscal first quarter 2022 financial results and provides business update

Cranford, n.j., feb. 10, 2022 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today reported business and financial results for the first fiscal quarter of 2022 ended december 31, 2021.
CTXR Ratings Summary
CTXR Quant Ranking